HCM HUTCHMED (China) Limited

Price (delayed)

$11.01

Market cap

$1.92B

P/E Ratio

4.15

Dividend/share

N/A

EPS

$2.65

Enterprise value

$1.95B

?
Relative Growth: Rel. Growth: 31
Relative Strength: Rel. Strength: 17
Relative Valuation: Rel. Valuation: 86
Relative Profitability: Rel. Profitability: 83

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company ...

Highlights
The company's quick ratio has surged by 84% YoY
The equity has surged by 63% year-on-year
The gross profit has contracted by 25% YoY
The company's gross margin fell by 13% YoY

Key stats

What are the main financial stats of HCM

HCM stock price

How has the HUTCHMED (China) Limited stock price performed over time
Intraday
0.46%
1 week
1.57%
1 month
7.21%
1 year
-38.08%
YTD
-17.4%
QTD
2.32%

Financial performance

How have HUTCHMED (China) Limited's revenue and profit performed over time
Revenue
$548.51M
Gross profit
$212.16M
Operating income
-$39.16M
Net income
$456.91M
Gross margin
38.7%
Net margin
83.3%
The gross profit has contracted by 25% YoY
The company's gross margin fell by 13% YoY
HUTCHMED (China) Limited's revenue has decreased by 13% YoY
The operating income has grown by 10% YoY

Price vs fundamentals

How does HCM's price correlate with its fundamentals

Growth

What is HUTCHMED (China) Limited's growth rate over time

Valuation

What is HUTCHMED (China) Limited stock price valuation
P/E
4.15
P/B
1.55
P/S
3.45
EV/EBIT
3.72
EV/EBITDA
N/A
EV/Sales
3.55
The equity has surged by 63% year-on-year
HUTCHMED (China) Limited's revenue has decreased by 13% YoY

Efficiency

How efficient is HUTCHMED (China) Limited business performance

Dividends

What is HCM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HCM.

Financial health

How did HUTCHMED (China) Limited financials performed over time
The company's quick ratio has surged by 84% YoY
HCM's current ratio has surged by 75% year-on-year
The debt is 92% smaller than the equity
The equity has surged by 63% year-on-year
HCM's debt to equity is down by 33% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.